Staten Biotechnology BV logo

Staten Biotechnology BV

Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet medical need in dyslipidemia. Dyslipidemia is an abnormal amount of lipids or fat in the blood, namely triglycerides, cholesterol, or fat phospholipids. In developed countries most dyslipidemias are hyperlipidemia, i.e. elevation of lipids in the blood, and can be caused by genetic factors, diet, and lifestyle.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.statenbiotech.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Transistorweg 5J6534 AT
Nijmegen
Netherlands
Email
Contact Number
+31 35 760 65 00

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]